When do biologic drug patents expire and when will biosimilars launch?

United States Patent 5,051,408 (Inulin Gamma Polymorph) Claims and US Patent Landscape Analysis

Executive summary

US Patent 5,051,408 covers a narrow but defensible concept: gamma-polymorphic inulin particles that are “virtually insoluble” in water at 37°C, with specific molecular weight ranges and submicron particle sizing in a stable suspension, plus downstream immunotherapy uses tied to activation of the alternative pathway of complement (APC). The enforcement risk is driven less by the breadth of administration routes (claims 9–10) and more by (i) whether later competitors use gamma-polymorph inulin and meet the insolubility and size requirements, and (ii) whether they position APC activation or inulin-as-adjuvant as the functional result. The remainder of the landscape likely turns on: earlier disclosures of gamma inulin polymorphs, particle-size and stable suspension formulations, complement activation by immunomodulators/adjuvants, and later improvements that either change polymorph, particle characteristics, or mechanism.

What exactly does US 5,051,408 claim about gamma inulin particles and “virtually insoluble” at 37°C?

Answer: The independent claim 1 is a composition claim limited to inulin particles that are (a) in the gamma polymorphic form and (b) “virtually insoluble in aqueous media at 37°C.” Dependent claims add molecular weight limits, a 8,000–16,000 range, and submicron particle sizing (<1 μm) in a “stable pure suspension.”

Claim 1: gamma polymorphic inulin particles with low solubility at 37°C

Scope trigger: “gamma polymorphic form”
Performance trigger: “virtually insoluble in aqueous media at 37°C”
Practical implication for design-arounds: If a competitor uses beta or alpha polymorph, amorphous inulin, or a different polymorphic state, they can fall outside claim 1 even if solubility is also low. If they stay gamma but alter the solubility profile (by particle treatment, hydration state, salts, or processing), they may avoid “virtually insoluble at 37°C.”

Claim 2: molecular weight > 8,000

Scope trigger: average molecular weight threshold.
Design-around logic: using lower MW gamma inulin or generating a distribution that fails “> 8,000” on relevant testing.

Claim 3: gamma inulin MW 8,000–16,000 and insoluble at 37°C

Scope trigger: MW window plus insolubility at 37°C.
Enforcement note: Range claims are often easier to target with analytical characterization, but easier to avoid by shifting MW outside the range.

Claim 4: stable pure suspension with particles <1 μm

Scope trigger: particle size cutoff plus formulation stability.
Key technical levers: milling/jet milling, dispersion stabilizers (though the claim says “pure suspension”), and re-agglomeration control.

What immunotherapeutic claims are tied to activation of the alternative pathway of complement (APC) in US 5,051,408?

Answer: Claims 5–6 and methods 14–16 tie APC activation to administration of gamma-polymorphic, virtually insoluble inulin particles (plus a pharmaceutically acceptable diluent/carrier), with additional claims using the inulin preparation to enhance immune response and vaccine or immune-modulator effects.

Claim 5: immunotherapeutic preparation for APC activation

Core elements:

active component = gamma inulin particles
insolubility at 37°C
pharmaceutically acceptable diluent/carrier

Functional result linkage: The therapeutic purpose is “activation of the alternate pathway of complement (APC).” This creates an arguments battleground: claim construction often treats such recitations as limiting depending on how the patent frames them, but the presence of “active component” language still anchors infringement to the gamma-insoluble inulin particle product.

Claim 6: active component comprises particles of gamma inulin

This is essentially a restatement narrowing to the gamma inulin composition.

Claims 14–16: methods of administering an effective amount

Claim 14: method for APC activation by administering an effective amount of the immunotherapeutic preparation.
Claim 15: method to enhance immune response to an immune modulator by administering the preparation.
Claim 16: method to enhance effect of a vaccinating antigen or peptide or anti-idiotype antibody by administering the inulin as an adjuvant.

Why these claims matter commercially: They allow the patent holder to pursue “adjunct” positioning even if the gamma inulin is not the primary biologic, so long as the method is practiced as claimed (effective amount for the functional enhancement/APC activation).

Which formulation and route-of-administration limitations are included in US 5,051,408 claims 7–10?

Answer: Claims 7–10 expand use into multiple administration routes, with specific vehicle features for at least injection and aqueous isotonic carriers.

Claim 7: sterile aqueous vehicle (carrier/diluent)

“sterile, aqueous vehicle” limits to aqueous formulations.
Design-around: non-aqueous carriers, lyophilized solid forms reconstituted differently, or non-sterile contexts (though sterilized pharma is typical).

Claim 8: isotonic solution

More specific: isotonicity can be a second axis to avoid.

Claim 9: suitable for injection

Broad within sterile pharmaceutical practice.

Claim 10: suitable for oral, rectal, vaginal, topical, nasal or ocular

This is broad and can support enforcement across many delivery formats.
Design-around: specific route limitations generally harder to use when claims explicitly cover multiple routes.

What immune-modulator and adjuvant combinations are claimed in US 5,051,408 claims 11–13 and 16?

Answer: The patent claims use as an adjuvant with a wide set of immune modulators, including cytokines, interferons, tumor necrosis factor, thymocyte stimulators, microbial components, and endotoxin. Claim 16 further ties the inulin to enhancing effect of vaccine antigens or antigenic peptides or anti-idiotype immunoglobulins.

Claim 11–13: immune modulator breadth

Claim 11: second active component is an immune modulator.
Claim 12: vaccinating antigen, antigenic peptide, or anti-idiotype immune globulin.
Claim 13: includes cytokines/lymphokines (ILs, IFNs, TNF, other lymphokines), thymus stimulators, microbial components (muramyl peptides, microbial components, whole microbes), or endotoxin.

Enforcement impact:

This breadth expands potential license or litigation targets: any inulin-as-adjuvant regimen involving those immune modulators could be argued within the claim.
However, proof of “effective amount” and “APC activation” may be contested if later products aim at different immune pathways or avoid complement activation.

How strong is US 5,051,408 against obvious design-arounds based on polymorph, solubility, and particle size?

Answer: The strongest claim anchors are the gamma polymorph designation and the performance limitation of “virtually insoluble” at 37°C, with additional narrowness in MW and particle size. These features create concrete infringement variables for testing and expert analysis.

Likely infringement “tripwires”

Polymorph identity (gamma)
Solubility profile at 37°C
Molecular weight windows
Particle size <1 μm (only for claim 4 and dependent structures)
Stable suspension characterization (claim 4 phrasing)

Likely weaker angles

Route-of-administration is broad; design-arounds by choosing a route may be harder.
Adjuvant/immune modulator is broad; but if a product uses a different functional mechanism or does not practice the method “for APC activation” or “enhancement” under claimed conditions, the legal linkage can be contested.

What does the claim set suggest about the implied invention scope and prior-art exposure?

Answer: The patent’s novelty likely centers on a specific solid-state form (gamma polymorph) of inulin and the resulting biological compatibility or immunological effect attributed to low solubility at body temperature, in a formulation suitable for administration.

Exposure to prior art likely concentrates on:

prior disclosures of inulin polymorphs and their stability
earlier gamma inulin preparation methods and characterization
prior use of inulin as an immunomodulator or adjuvant
prior disclosures of complement activation therapies
prior formulation work on submicron carbohydrate particles or stable suspensions

Without the written description and prosecution history, the exact novelty boundary cannot be mapped precisely, but the claim structure shows the intended novelty resides in the particle attributes and the APC-linked functional use.

What US patent landscape typically surrounds gamma polymorphic inulin, APC activation, and inulin as an adjuvant?

Answer: The landscape is likely segmented into three clusters: (1) carbohydrate solid-state form/polymorph and particle engineering, (2) complement-pathway activation and immunotherapy compositions, and (3) use of polysaccharides or carbohydrate particles as vaccine adjuvants/immunomodulators.

Cluster 1: polymorphs and particle-engineered inulin

Key questions for a freedom-to-operate search:

Are there earlier patents that already disclose “gamma” inulin as a distinct polymorph?
Do earlier references teach body-temperature insolubility or analogous solubility-lowering steps?
Do earlier formulations achieve submicron dispersions without stabilizers that would still read on “pure suspension”?

Cluster 2: APC activation immunotherapy

Key questions:

Are there earlier APC activators or complement pathway modulators used as therapeutics?
Do those therapies specify carbohydrate particles, or do they rely on proteins, antibodies, or small molecules?
Do any older claims cover APC activation by administering “effective amounts” of specific particles?

Cluster 3: adjuvants and immune enhancement

Key questions:

Does the landscape include polysaccharide adjuvants that are similar in mechanism and formulation type?
Is there overlap with cytokines, microbial components, or endotoxin-based adjuvant regimens?

When does US 5,051,408 expire in the US, and what are the key exclusivity considerations?

Answer: Patent term for US utility patents is generally 20 years from the earliest effective US filing date, subject to any adjustments. Determining the exact expiry date requires the priority/filing history and any Patent Term Adjustment (PTA) granted for US 5,051,408.

Because only the claim text was provided, a precise expiry date cannot be computed here without the filing/priority data from the patent front page.

Which infringement theories are most plausible for US 5,051,408 (composition vs method vs combination)?

Answer: For gamma insoluble inulin products, composition claims 1–4 and immunotherapeutic claim 5 are the most direct. For adjuvant regimens, method claims 14–16 create a pathway to enforce against combination therapy workflows even where gamma inulin is not the primary active ingredient.

Composition infringement

Manufacturing or selling gamma-polymorph inulin particles that are virtually insoluble at 37°C.

Method infringement

Administering an effective amount to activate APC, or to enhance immune responses or vaccine effects.

Combination/adjunct infringement

Using the inulin preparation alongside immune modulators (claims 11–13 and claim 16).
This is the most commercially actionable path if the inulin is positioned as an adjuvant.

What generic entry risks exist if a competitor tries to sell “insoluble inulin” or “gamma inulin” products?

Answer: If a generic/biosimilar-style entry is attempted (despite inulin not being a biologic), risk turns on whether the entrant’s product meets the polymorph, solubility, MW, and particle size constraints of the claims.

High-risk entry profiles

Product marketed or tested as “gamma inulin” and shown to be body-temperature insoluble.
Particle-engineered submicron suspension claims.
Combination products or regimens using immune modulators and explicitly or implicitly aimed at APC activation or immune enhancement.

Lower-risk entry profiles

Non-gamma polymorphs (alpha/beta/amorphous) or different solid-state states.
Different solubility profile at 37°C.
Different particle size distribution outside <1 μm (for claim 4).
Avoidance of the APC activation functional use in clinical positioning, and lack of practice of the method claims (still subject to evidence of actual biological effect and dosing).

How does US 5,051,408 compare with typical “carbohydrate adjuvant” patents in claim structure?

Answer: It is more formulation- and solid-state-specific than many carbohydrate adjuvant patents. Rather than claiming a broad immunostimulant class, it locks to:

a specific inulin polymorph (gamma),
a physicochemical property at 37°C (virtually insoluble),
and a particle size stability constraint in the narrowest dependent claim.

This structure usually improves enforceability by giving expert test criteria for infringement and narrowing prior-art overlap.

Key Takeaways

US 5,051,408’s core protection is the combination of gamma-polymorphic inulin particles and near-insolubility in aqueous media at 37°C.
Dependent claims tighten protection via molecular weight ranges (notably 8,000–16,000) and, in one claim, submicron stable suspensions (<1 μm).
Commercially, the most enforceable downstream hooks are the APC activation use and adjuvant/enhancement methods, especially when gamma inulin is used alongside immune modulators or vaccine antigens.
Design-arounds are most plausible through changing polymorph identity, shifting molecular weight, altering solubility at 37°C, and changing particle size/distribution.
Route-of-administration breadth is high; focusing on route alone is unlikely to avoid infringement.
A precise expiry date and full landscape mapping require the patent front-page bibliographic data (priority/filing and PTA), plus citation and prosecution records, which were not included in the provided input.

FAQs

1) Does US 5,051,408 require a specific dosage or “effective amount” range?
The claims use functional “effective amount” language for administration and enhancement/APC activation, but specific numerical dosage ranges are not contained in the claim excerpt provided.

2) Can a competitor avoid infringement by using a different inulin polymorph?
If the product is not gamma polymorphic inulin, it may fall outside claims requiring “gamma polymorphic form.”

3) Is submicron particle size required for all claims?
No. Sub-1 μm sizing is in claim 4, and only those formulations seeking the claim 4 tier must meet that constraint.

4) What is the practical evidence needed to prove “virtually insoluble at 37°C”?
In practice, infringement would rely on solubility testing or comparable characterization demonstrating that the formulation meets the patent’s “virtually insoluble” threshold at 37°C.

5) Does the patent cover oral and topical uses?
Yes. Claim 10 includes oral, rectal, vaginal, topical, nasal, and ocular administration, along with injection in claim 9.

References (APA)

United States Patent 5,051,408.

Title:	Inulin compositions in gamma polymorphic form
Abstract:	A process for preparing gamma inulin comprising the steps of (a) recrystallizing crude inulin from water at a temperature below 37.degree. C. to obtain a suspension, (b) heating the suspension at a temperature of from about 25.degree. to 45.degree. C. for about 1-3 days, (c) further heating the suspension at a temperature of about 40.degree. to 55.degree. C. for about 0.5 to 1.5 hours, and (d) isolating insoluble gamma inulin from the suspension. A composition comprising particles of inulin or an inulin derivative in the gamma polymorphic form is characterized in that the particles have a low rate of solution in aqueous media above 30.degree. C., particularly above 37.degree. C. The composition is effective as the active component of an immunotherapeutic preparation for activation of the alternative pathway of complement, or for antitumor treatment.
Inventor(s):	Cooper; Peter Dodd (Monash, AU)
Assignee:	The Australian National University (Acton, AU)
Application Number:	07/501,752
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	United States Patent 5,051,408 (Inulin Gamma Polymorph) Claims and US Patent Landscape Analysis Executive summary US Patent 5,051,408 covers a narrow but defensible concept: gamma-polymorphic inulin particles that are “virtually insoluble” in water at 37°C, with specific molecular weight ranges and submicron particle sizing in a stable suspension, plus downstream immunotherapy uses tied to activation of the alternative pathway of complement (APC). The enforcement risk is driven less by the breadth of administration routes (claims 9–10) and more by (i) whether later competitors use gamma-polymorph inulin and meet the insolubility and size requirements, and (ii) whether they position APC activation or inulin-as-adjuvant as the functional result. The remainder of the landscape likely turns on: earlier disclosures of gamma inulin polymorphs, particle-size and stable suspension formulations, complement activation by immunomodulators/adjuvants, and later improvements that either change polymorph, particle characteristics, or mechanism. What exactly does US 5,051,408 claim about gamma inulin particles and “virtually insoluble” at 37°C? Answer: The independent claim 1 is a composition claim limited to inulin particles that are (a) in the gamma polymorphic form and (b) “virtually insoluble in aqueous media at 37°C.” Dependent claims add molecular weight limits, a 8,000–16,000 range, and submicron particle sizing (<1 μm) in a “stable pure suspension.” Claim 1: gamma polymorphic inulin particles with low solubility at 37°C Scope trigger: “gamma polymorphic form” Performance trigger: “virtually insoluble in aqueous media at 37°C” Practical implication for design-arounds: If a competitor uses beta or alpha polymorph, amorphous inulin, or a different polymorphic state, they can fall outside claim 1 even if solubility is also low. If they stay gamma but alter the solubility profile (by particle treatment, hydration state, salts, or processing), they may avoid “virtually insoluble at 37°C.” Claim 2: molecular weight > 8,000 Scope trigger: average molecular weight threshold. Design-around logic: using lower MW gamma inulin or generating a distribution that fails “> 8,000” on relevant testing. Claim 3: gamma inulin MW 8,000–16,000 and insoluble at 37°C Scope trigger: MW window plus insolubility at 37°C. Enforcement note: Range claims are often easier to target with analytical characterization, but easier to avoid by shifting MW outside the range. Claim 4: stable pure suspension with particles <1 μm Scope trigger: particle size cutoff plus formulation stability. Key technical levers: milling/jet milling, dispersion stabilizers (though the claim says “pure suspension”), and re-agglomeration control. What immunotherapeutic claims are tied to activation of the alternative pathway of complement (APC) in US 5,051,408? Answer: Claims 5–6 and methods 14–16 tie APC activation to administration of gamma-polymorphic, virtually insoluble inulin particles (plus a pharmaceutically acceptable diluent/carrier), with additional claims using the inulin preparation to enhance immune response and vaccine or immune-modulator effects. Claim 5: immunotherapeutic preparation for APC activation Core elements: active component = gamma inulin particles insolubility at 37°C pharmaceutically acceptable diluent/carrier Functional result linkage: The therapeutic purpose is “activation of the alternate pathway of complement (APC).” This creates an arguments battleground: claim construction often treats such recitations as limiting depending on how the patent frames them, but the presence of “active component” language still anchors infringement to the gamma-insoluble inulin particle product. Claim 6: active component comprises particles of gamma inulin This is essentially a restatement narrowing to the gamma inulin composition. Claims 14–16: methods of administering an effective amount Claim 14: method for APC activation by administering an effective amount of the immunotherapeutic preparation. Claim 15: method to enhance immune response to an immune modulator by administering the preparation. Claim 16: method to enhance effect of a vaccinating antigen or peptide or anti-idiotype antibody by administering the inulin as an adjuvant. Why these claims matter commercially: They allow the patent holder to pursue “adjunct” positioning even if the gamma inulin is not the primary biologic, so long as the method is practiced as claimed (effective amount for the functional enhancement/APC activation). Which formulation and route-of-administration limitations are included in US 5,051,408 claims 7–10? Answer: Claims 7–10 expand use into multiple administration routes, with specific vehicle features for at least injection and aqueous isotonic carriers. Claim 7: sterile aqueous vehicle (carrier/diluent) “sterile, aqueous vehicle” limits to aqueous formulations. Design-around: non-aqueous carriers, lyophilized solid forms reconstituted differently, or non-sterile contexts (though sterilized pharma is typical). Claim 8: isotonic solution More specific: isotonicity can be a second axis to avoid. Claim 9: suitable for injection Broad within sterile pharmaceutical practice. Claim 10: suitable for oral, rectal, vaginal, topical, nasal or ocular This is broad and can support enforcement across many delivery formats. Design-around: specific route limitations generally harder to use when claims explicitly cover multiple routes. What immune-modulator and adjuvant combinations are claimed in US 5,051,408 claims 11–13 and 16? Answer: The patent claims use as an adjuvant with a wide set of immune modulators, including cytokines, interferons, tumor necrosis factor, thymocyte stimulators, microbial components, and endotoxin. Claim 16 further ties the inulin to enhancing effect of vaccine antigens or antigenic peptides or anti-idiotype immunoglobulins. Claim 11–13: immune modulator breadth Claim 11: second active component is an immune modulator. Claim 12: vaccinating antigen, antigenic peptide, or anti-idiotype immune globulin. Claim 13: includes cytokines/lymphokines (ILs, IFNs, TNF, other lymphokines), thymus stimulators, microbial components (muramyl peptides, microbial components, whole microbes), or endotoxin. Enforcement impact: This breadth expands potential license or litigation targets: any inulin-as-adjuvant regimen involving those immune modulators could be argued within the claim. However, proof of “effective amount” and “APC activation” may be contested if later products aim at different immune pathways or avoid complement activation. How strong is US 5,051,408 against obvious design-arounds based on polymorph, solubility, and particle size? Answer: The strongest claim anchors are the gamma polymorph designation and the performance limitation of “virtually insoluble” at 37°C, with additional narrowness in MW and particle size. These features create concrete infringement variables for testing and expert analysis. Likely infringement “tripwires” Polymorph identity (gamma) Solubility profile at 37°C Molecular weight windows Particle size <1 μm (only for claim 4 and dependent structures) Stable suspension characterization (claim 4 phrasing) Likely weaker angles Route-of-administration is broad; design-arounds by choosing a route may be harder. Adjuvant/immune modulator is broad; but if a product uses a different functional mechanism or does not practice the method “for APC activation” or “enhancement” under claimed conditions, the legal linkage can be contested. What does the claim set suggest about the implied invention scope and prior-art exposure? Answer: The patent’s novelty likely centers on a specific solid-state form (gamma polymorph) of inulin and the resulting biological compatibility or immunological effect attributed to low solubility at body temperature, in a formulation suitable for administration. Exposure to prior art likely concentrates on: prior disclosures of inulin polymorphs and their stability earlier gamma inulin preparation methods and characterization prior use of inulin as an immunomodulator or adjuvant prior disclosures of complement activation therapies prior formulation work on submicron carbohydrate particles or stable suspensions Without the written description and prosecution history, the exact novelty boundary cannot be mapped precisely, but the claim structure shows the intended novelty resides in the particle attributes and the APC-linked functional use. What US patent landscape typically surrounds gamma polymorphic inulin, APC activation, and inulin as an adjuvant? Answer: The landscape is likely segmented into three clusters: (1) carbohydrate solid-state form/polymorph and particle engineering, (2) complement-pathway activation and immunotherapy compositions, and (3) use of polysaccharides or carbohydrate particles as vaccine adjuvants/immunomodulators. Cluster 1: polymorphs and particle-engineered inulin Key questions for a freedom-to-operate search: Are there earlier patents that already disclose “gamma” inulin as a distinct polymorph? Do earlier references teach body-temperature insolubility or analogous solubility-lowering steps? Do earlier formulations achieve submicron dispersions without stabilizers that would still read on “pure suspension”? Cluster 2: APC activation immunotherapy Key questions: Are there earlier APC activators or complement pathway modulators used as therapeutics? Do those therapies specify carbohydrate particles, or do they rely on proteins, antibodies, or small molecules? Do any older claims cover APC activation by administering “effective amounts” of specific particles? Cluster 3: adjuvants and immune enhancement Key questions: Does the landscape include polysaccharide adjuvants that are similar in mechanism and formulation type? Is there overlap with cytokines, microbial components, or endotoxin-based adjuvant regimens? When does US 5,051,408 expire in the US, and what are the key exclusivity considerations? Answer: Patent term for US utility patents is generally 20 years from the earliest effective US filing date, subject to any adjustments. Determining the exact expiry date requires the priority/filing history and any Patent Term Adjustment (PTA) granted for US 5,051,408. Because only the claim text was provided, a precise expiry date cannot be computed here without the filing/priority data from the patent front page. Which infringement theories are most plausible for US 5,051,408 (composition vs method vs combination)? Answer: For gamma insoluble inulin products, composition claims 1–4 and immunotherapeutic claim 5 are the most direct. For adjuvant regimens, method claims 14–16 create a pathway to enforce against combination therapy workflows even where gamma inulin is not the primary active ingredient. Composition infringement Manufacturing or selling gamma-polymorph inulin particles that are virtually insoluble at 37°C. Method infringement Administering an effective amount to activate APC, or to enhance immune responses or vaccine effects. Combination/adjunct infringement Using the inulin preparation alongside immune modulators (claims 11–13 and claim 16). This is the most commercially actionable path if the inulin is positioned as an adjuvant. What generic entry risks exist if a competitor tries to sell “insoluble inulin” or “gamma inulin” products? Answer: If a generic/biosimilar-style entry is attempted (despite inulin not being a biologic), risk turns on whether the entrant’s product meets the polymorph, solubility, MW, and particle size constraints of the claims. High-risk entry profiles Product marketed or tested as “gamma inulin” and shown to be body-temperature insoluble. Particle-engineered submicron suspension claims. Combination products or regimens using immune modulators and explicitly or implicitly aimed at APC activation or immune enhancement. Lower-risk entry profiles Non-gamma polymorphs (alpha/beta/amorphous) or different solid-state states. Different solubility profile at 37°C. Different particle size distribution outside <1 μm (for claim 4). Avoidance of the APC activation functional use in clinical positioning, and lack of practice of the method claims (still subject to evidence of actual biological effect and dosing). How does US 5,051,408 compare with typical “carbohydrate adjuvant” patents in claim structure? Answer: It is more formulation- and solid-state-specific than many carbohydrate adjuvant patents. Rather than claiming a broad immunostimulant class, it locks to: a specific inulin polymorph (gamma), a physicochemical property at 37°C (virtually insoluble), and a particle size stability constraint in the narrowest dependent claim. This structure usually improves enforceability by giving expert test criteria for infringement and narrowing prior-art overlap. Key Takeaways US 5,051,408’s core protection is the combination of gamma-polymorphic inulin particles and near-insolubility in aqueous media at 37°C. Dependent claims tighten protection via molecular weight ranges (notably 8,000–16,000) and, in one claim, submicron stable suspensions (<1 μm). Commercially, the most enforceable downstream hooks are the APC activation use and adjuvant/enhancement methods, especially when gamma inulin is used alongside immune modulators or vaccine antigens. Design-arounds are most plausible through changing polymorph identity, shifting molecular weight, altering solubility at 37°C, and changing particle size/distribution. Route-of-administration breadth is high; focusing on route alone is unlikely to avoid infringement. A precise expiry date and full landscape mapping require the patent front-page bibliographic data (priority/filing and PTA), plus citation and prosecution records, which were not included in the provided input. FAQs 1) Does US 5,051,408 require a specific dosage or “effective amount” range? The claims use functional “effective amount” language for administration and enhancement/APC activation, but specific numerical dosage ranges are not contained in the claim excerpt provided. 2) Can a competitor avoid infringement by using a different inulin polymorph? If the product is not gamma polymorphic inulin, it may fall outside claims requiring “gamma polymorphic form.” 3) Is submicron particle size required for all claims? No. Sub-1 μm sizing is in claim 4, and only those formulations seeking the claim 4 tier must meet that constraint. 4) What is the practical evidence needed to prove “virtually insoluble at 37°C”? In practice, infringement would rely on solubility testing or comparable characterization demonstrating that the formulation meets the patent’s “virtually insoluble” threshold at 37°C. 5) Does the patent cover oral and topical uses? Yes. Claim 10 includes oral, rectal, vaginal, topical, nasal, and ocular administration, along with injection in claim 9. References (APA) United States Patent 5,051,408. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	BAYGAM, GAMASTAN S/D	immune globulin (human)	Injection	101134	January 11, 1944	⤷ Start Trial	2010-03-30
Grifols Therapeutics Llc	GAMMAKED, GAMUNEX-C	immune globulin injection (human) 10% caprylate/chromatography purified	Injection	125046	August 27, 2003	⤷ Start Trial	2010-03-30
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	May 21, 2004	⤷ Start Trial	2010-03-30
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	March 26, 2007	⤷ Start Trial	2010-03-30
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	July 11, 2014	⤷ Start Trial	2010-03-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Summary for Patent: 5,051,408